Healthcare

Celltrion

068270

Eli Lilly & Co.

LLY

Biosimilars vs novel drugs - Korea vs US bio blue chip investment comparison

Celltrion

068270

KRX

₩190,000

▲ 3,000 (+1.60%)

Korea's largest biosimilar company. Global sales of blockbuster biosimilars including Remsima and Truxima.

Eli Lilly & Co.

LLY

NYSE/NASDAQ

$820.50

▲ 15.3 (+1.90%)

Explosive growth with GLP-1 obesity/diabetes drugs Mounjaro/Zepbound. Global top 10 pharma by market cap.

主要指標比較

Celltrion

主要指標比較

Eli Lilly & Co.

₩190,000

Price

$820.50

+1.60%

Change

+1.90%

22.7

P/E Ratio

68.4

₩40.8조

Market Cap

$780B

₩230,000

52W High

$950.00

₩165,000

52W Low

$580.00

1.3M

Volume

5.2M

About the Companies

Celltrion

Korea's largest biosimilar company. Global sales of blockbuster biosimilars including Remsima and Truxima.

Eli Lilly & Co.

Explosive growth with GLP-1 obesity/diabetes drugs Mounjaro/Zepbound. Global top 10 pharma by market cap.

※ All data is for reference only and not real-time. Investment decisions are the sole responsibility of the investor. This comparison is not investment advice.

Other Comparisons

Celltrion vs Samsung Biologics

Healthcare

Eli Lilly & Co. vs UnitedHealth Group

Healthcare

Samsung Biologics vs UnitedHealth Group

Healthcare

Samsung Electronics vs Celltrion

blue-chip

SK Hynix vs Celltrion

Hyundai Motor vs Celltrion

blue-chip

LG Energy Solution vs Celltrion

blue-chip